JANUARY/FEBRUARY

Vol 9, No 1 CME Pretest

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicians can earn 4 credit hours of Category 1 for the Physician's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions in the posttest at the end of this issue. Complete instructions are given on the posttest pages. Successfully answering 30 or more questions will earn 4 credit hours. CME is presented by an unrestricted educational grant from Bristol-Myers Squibb Oncology Division.

Educational Objectives

After reading this issue of Cancer Control, clinicians will be expected to:

• describe recent changes in staging of melanoma,

• understand adjuvant therapy of melanoma with interferon,

• recognize the potential of biochemotherapy and experimental approaches to the treatment of melanoma, and

• appreciate the role of hepatic surgery for metastatic neuroendocrine tumors.

This program was planned in accordance with ACCME Essentials.

Release Date: January 1, 2002
Expiration Date: January 1, 2003

1. The prognosis for a patient with a primary melanoma and an “in-transit” metastasis or satellite lesions without lymph node metastasis is:

a. inferior to patients with node metastases
b. better than patients with node metastasis
c. highly variable and unpredictable
d. similar to patients with node metastases

2. Phase III randomized trials indicate that the “Dartmouth” combination chemotherapy regimen used to treat metastatic melanoma differs from dacarbazine (DTIC) in that it produces:

a. more remissions
b. more toxicity
c. longer survival
d. longer remissions

3. Neuroendocrine metastases in the liver tend to have what relationship with the major intrahepatic vasculature or bile ducts?

a. displace
b. obstruct
c. invade
d. encase